Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
25 participants
OBSERVATIONAL
2022-05-02
2025-06-13
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Healthy Ageing: a Feasibility Study to Evaluate Digitally-enabled Ways to Support Healthy Ageing
NCT07112352
The Kunshan Elderly Health Study
NCT05141565
Prescribing Smart Aging: Integrating Health Systems With Community-Based Lifestyle Interventions
NCT03253341
Improving Cardiac Secondary Prevention
NCT03269708
Applying Population Management Best Practices to Preventative Genomic Medicine Trial
NCT07053813
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AGE Participants
Participants aged 65 and older with diagnosis of solid tumor malignancy or lymphoma and planned to start a new chemotherapy regimen in the outpatient setting
Geriatric Assessments and Frailty Indices
Eligible and consented subjects will undergo a baseline assessment prior to chemotherapy initiation inclusive of geriatric/frailty assessments, patient reported outcomes and blood samples for biomarkers of aging. Assessment measures and blood samples will be repeated post cycle 1 and 2 of chemotherapy. Toxicity will be recorded from the medical record
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Geriatric Assessments and Frailty Indices
Eligible and consented subjects will undergo a baseline assessment prior to chemotherapy initiation inclusive of geriatric/frailty assessments, patient reported outcomes and blood samples for biomarkers of aging. Assessment measures and blood samples will be repeated post cycle 1 and 2 of chemotherapy. Toxicity will be recorded from the medical record
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Planned to initiate a new chemotherapy regimen
* Solid tumor malignancy of any stage or lymphoma
* Any performance status
* Ability to understand and the willingness to sign an IRB-approved informed consent document (either directly or via a legally authorized representative).
* Life expectancy of ≥3 months
Exclusion Criteria
* Hematologic malignancy other than lymphoma.
* Concurrent radiation therapy.
* Planned inpatient chemotherapy.
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Wake Forest University Health Sciences
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Heidi Klepin, MD, MS
Role: PRINCIPAL_INVESTIGATOR
Wake Forest Baptist Comprehensive Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Wake Forest Baptist Comprehensive Cancer Center
Winston-Salem, North Carolina, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
WFBCCC 04721
Identifier Type: OTHER
Identifier Source: secondary_id
IRB00080711
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.